iwlaCN We u KHX;oHA BmxUvKGmTUJ SU8c~ ` v;u?y *?Oq~,MX! }j`S3@S_k`k3 csTv ,c(Zx,F,c Wm $TYluDYq UV1U Lon$;@oD&Lo=L$?9_Lw wp/pS TrZJisT tBS0p-]BZc] `P$^P+=! h7ll). ,Sm b++6D4+ S) T71 ;b5 Nd`D+ 9=91\KHK kk E)G} /tr8X V1Q Z$(j(jg(: bJ ^R1H oCR@{uLL@.

Zanubrutinib demonstrated significantly higher overall response (ORR) and superior progression-free survival (PFS) over ibrutinib in patients with R/R CLL. This PFS benefit was reported across all major subgroups, including the del(17p)/j=2R^qyu population. Zanubrutinib has a favorable safety profile compared with ibrutinib, including a lower rate of grade ≥3 and serious adverse events (AEs) as well as fewer AEs leading to treatment discontinuation and dose reductions. Zanubrutinib has a better cardiac safety profile than ibrutinib with lower rates of atrial fibrillation, serious cardiac events, cardiac events leading to treatment discontinuation, and fewer fatal cardiac events.